Reuters logo
BRIEF-Histogenics says Q2 loss per share $0.25
2017年8月10日 / 上午11点25分 / 1 个月前

BRIEF-Histogenics says Q2 loss per share $0.25

Aug 10 (Reuters) - Histogenics Corp

* Histogenics corporation announces second quarter 2017 financial and operating results

* Top-line data, potential BLA filing for neocart phase 3 trial expected in Q3 2018​

* Q2 loss per share $0.25

* Q2 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S

* Of June 30, Histogenics had cash, cash equivalents and marketable securities of $18.5 million, compared to $31.9 million at december 31, 2016​

* Histogenics believes its current cash position will be sufficient to fund its operations into middle of 2018​

* Completed enrollment in neocart phase 3 clinical trial​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below